Cosgrove BD et al. |
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. |
2009 |
Toxicol. Appl. Pharmacol. |
pmid:19362101
|
Peters TS |
Do preclinical testing strategies help predict human hepatotoxic potentials? |
2005 |
Toxicol Pathol |
pmid:15805066
|
De Lorenzi G et al. |
Mycobacterium genavense Infection in a Domestic Ferret (Mustela putorius furo). |
2018 |
Top Companion Anim Med |
pmid:30502861
|
Mukae H et al. |
Low expression of T-cell co-stimulatory molecules in bone marrow-derived dendritic cells in a mouse model of chronic respiratory infection with Pseudomonas aeruginosa. |
2010 |
Tohoku J. Exp. Med. |
pmid:20046053
|
Kaji C et al. |
Antimicrobial effect of fluoroquinolones for the eradication of nontypeable Haemophilus influenzae isolates within biofilms. |
2008 |
Tohoku J. Exp. Med. |
pmid:18285669
|
Walrave TR et al. |
[Mania induced by antibiotic therapy]. |
|
Tijdschr Psychiatr |
pmid:27527887
|
Lygren I et al. |
[Treatment of Helicobacter pylori infection]. |
1998 |
Tidsskr. Nor. Laegeforen. |
pmid:9889634
|
Farup PG |
[Treatment of Helicobacter pylori infection--results and experiences with an Internet-based collaboration trial]. |
2003 |
Tidsskr. Nor. Laegeforen. |
pmid:14714012
|
Schweeger I et al. |
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. |
2000 |
Thromb. Res. |
pmid:10704650
|
van Ingen J et al. |
Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. |
2009 |
Thorax |
pmid:19213773
|
Andréjak C et al. |
Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. |
2009 |
Thorax |
pmid:19052044
|
Essilfie AT et al. |
Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. |
2015 |
Thorax |
pmid:25746630
|
Jenkins PA et al. |
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. |
2008 |
Thorax |
pmid:18250184
|
Majoor CJ et al. |
Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease. |
2004 |
Thorax |
pmid:15223876
|
Spencer S and Jones PW |
Time course of recovery of health status following an infective exacerbation of chronic bronchitis. |
2003 |
Thorax |
pmid:12832673
|
Brusselle GG |
Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases? |
2015 |
Thorax |
pmid:25870311
|
Pinzani V et al. |
[Occurrence of anterior uveitis in a HIV patient treated with rifabutin, ethambutol, clarithromycin]. |
1995 Sep-Oct |
Therapie |
pmid:8571297
|
Bohr UR and Malfertheiner P |
Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails. |
2009 |
Therap Adv Gastroenterol |
pmid:21180534
|
Berning M et al. |
Should quinolones come first in Helicobacter pylori therapy? |
2011 |
Therap Adv Gastroenterol |
pmid:21694812
|
Mégraud F |
The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. |
2012 |
Therap Adv Gastroenterol |
pmid:22423259
|
Gisbert JP |
Second-line rescue therapy of helicobacter pylori infection. |
2009 |
Therap Adv Gastroenterol |
pmid:21180581
|
Krause M |
[Resistance problems in gastrointestinal infections]. |
2002 |
Ther Umsch |
pmid:11851045
|
Niioka T et al. |
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. |
2006 |
Ther Drug Monit |
pmid:16778714
|
Kunicki PK and Sobieszczańska-Małek M |
Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. |
2005 |
Ther Drug Monit |
pmid:15665756
|
Zhou SF et al. |
Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. |
2007 |
Ther Drug Monit |
pmid:18043468
|
Zhanel GG et al. |
Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. |
2006 |
Ther Clin Risk Manag |
pmid:18360582
|
Nawarskas JJ and Snowden SS |
Critical appraisal of ticagrelor in the management of acute coronary syndrome. |
2011 |
Ther Clin Risk Manag |
pmid:22241944
|
Rafii F et al. |
Effects of treatment with antimicrobial agents on the human colonic microflora. |
2008 |
Ther Clin Risk Manag |
pmid:19337440
|
Chandwani A and Shuter J |
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. |
2008 |
Ther Clin Risk Manag |
pmid:19209283
|
Zhou S et al. |
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. |
2005 |
Ther Clin Risk Manag |
pmid:18360537
|
Hline SS et al. |
Conivaptan: a step forward in the treatment of hyponatremia? |
2008 |
Ther Clin Risk Manag |
pmid:18728836
|
Zong W et al. |
The first case of cutaneous infection with Mycobacterium parascrofulaceum. |
2012 |
Ther Clin Risk Manag |
pmid:22930638
|
Pace F et al. |
A review of rabeprazole in the treatment of acid-related diseases. |
2007 |
Ther Clin Risk Manag |
pmid:18488081
|
Oncü S |
Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin. |
2007 |
Ther Clin Risk Manag |
pmid:18488076
|
Duclos AJ et al. |
Current treatment options in the management of chronic prostatitis. |
2007 |
Ther Clin Risk Manag |
pmid:18472971
|
Ellsworth P |
Fesoterodine for the treatment of urinary incontinence and overactive bladder. |
2009 |
Ther Clin Risk Manag |
pmid:19956551
|
Carrie AG and Marrie TJ |
Use of intravenous antibiotics for the treatment of community-acquired pneumonia in the emergency department. |
2005 |
Ther Clin Risk Manag |
pmid:18360543
|
Goodman JJ and Martin SI |
Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. |
2012 |
Ther Clin Risk Manag |
pmid:22547933
|
Werth S et al. |
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. |
2012 |
Ther Clin Risk Manag |
pmid:22547932
|
Quan F et al. |
Investigation of pulmonary infection pathogens in neurological intensive care unit. |
2011 |
Ther Clin Risk Manag |
pmid:21339939
|
Neely M and Kovacs A |
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. |
2009 |
Ther Clin Risk Manag |
pmid:19707276
|
Coeman M et al. |
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. |
2011 |
Ther Adv Respir Dis |
pmid:21890536
|
Minushkin ON et al. |
[Age and eradication treatment of duodenal ulcer]. |
2007 |
Ter. Arkh. |
pmid:17460963
|
Vasil'ev IuV et al. |
[Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. |
2002 |
Ter. Arkh. |
pmid:12360599
|
Maev IV et al. |
[Eradication therapy for Helicobacter pylori infection: review of world trends]. |
2014 |
Ter. Arkh. |
pmid:24779078
|
Tsukanov VV et al. |
[Helicobacter pylori eradication: current status]. |
2013 |
Ter. Arkh. |
pmid:23653944
|
Maev IV et al. |
[Experience in the use of losek (omeprazole) in gastroenterology]. |
2001 |
Ter. Arkh. |
pmid:11523419
|
Konorev MR |
[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy]. |
2012 |
Ter. Arkh. |
pmid:23479993
|
Kirika NV et al. |
[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer]. |
2004 |
Ter. Arkh. |
pmid:15106408
|
Isakov VA et al. |
[Results of an open multicenter study of the efficiency of one-week anti-helicobacter therapy using omeprazole, clarithromycin, and amoxicillin in patients with duodenal peptic ulcer]. |
2003 |
Ter. Arkh. |
pmid:14708448
|